Clinical Trial

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: * Belumosudil (an immunotherapy) * Fluticasone (an intranasal corticosteroid) * Azithromycin (an antibiotic) * Montelukast (a leukotriene receptor antagonist) * Prednisone (a corticosteroid)
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-06-19; most recent amendment 2026-06-08.
Status change: Not Yet Recruiting → Recruiting 2024-01-16
Trial Details
NCT Number NCT05922761
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Sanofi, National Heart, Lung, and Blood Institute (NHLBI)
Conditions Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans, Lung Diseases, Chronic Graft Versus Host Disease
Enrollment 45 participants
Start Date 2024-05-31
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-10